DK2705143T3 - Protein-induceret pluripotent celleteknologi og anvendelse deraf - Google Patents

Protein-induceret pluripotent celleteknologi og anvendelse deraf Download PDF

Info

Publication number
DK2705143T3
DK2705143T3 DK12779306.5T DK12779306T DK2705143T3 DK 2705143 T3 DK2705143 T3 DK 2705143T3 DK 12779306 T DK12779306 T DK 12779306T DK 2705143 T3 DK2705143 T3 DK 2705143T3
Authority
DK
Denmark
Prior art keywords
protein
induced pluripotent
pluripotent cell
cell technology
technology
Prior art date
Application number
DK12779306.5T
Other languages
English (en)
Inventor
Jianjun Wang
Qianqian Li
Original Assignee
Univ Wayne State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wayne State filed Critical Univ Wayne State
Application granted granted Critical
Publication of DK2705143T3 publication Critical patent/DK2705143T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK12779306.5T 2011-05-02 2012-05-02 Protein-induceret pluripotent celleteknologi og anvendelse deraf DK2705143T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161481273P 2011-05-02 2011-05-02
PCT/US2012/036051 WO2012151234A2 (en) 2011-05-02 2012-05-02 A protein-induced pluripotent cell technology uses thereof

Publications (1)

Publication Number Publication Date
DK2705143T3 true DK2705143T3 (da) 2021-05-10

Family

ID=47108197

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12779306.5T DK2705143T3 (da) 2011-05-02 2012-05-02 Protein-induceret pluripotent celleteknologi og anvendelse deraf

Country Status (8)

Country Link
US (4) US9816076B2 (da)
EP (2) EP3777538B1 (da)
CN (2) CN103826459B (da)
DK (1) DK2705143T3 (da)
ES (2) ES2957478T3 (da)
PL (1) PL2705143T3 (da)
PT (1) PT2705143T (da)
WO (1) WO2012151234A2 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
ES2957478T3 (es) * 2011-05-02 2024-01-19 Univ Wayne State Una tecnología de células madre pluripotentes inducidas por proteínas y usos de las mismas
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
MX2014007233A (es) 2011-12-16 2015-02-04 Moderna Therapeutics Inc Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
KR20200057108A (ko) * 2013-10-25 2020-05-25 웨인 스테이트 유니버시티 단백질-유도 생체내 세포 재프로그래밍을 통한 세포 전환 방법, 시스템 및 조성물
KR101781693B1 (ko) * 2015-09-24 2017-09-26 서울대학교병원 심장내막 유래 성체줄기세포로부터 제조된 유도만능 줄기세포의 심혈관계 세포로의 분화방법 및 이의 용도
GB201909975D0 (en) * 2019-07-11 2019-08-28 Babraham Inst Novel reprogramming method
US20230061798A1 (en) * 2020-01-24 2023-03-02 I Peace, Inc. Method for culturing factor-introduced cells

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
EP1407052B1 (en) 2001-07-06 2008-12-03 MERCK PATENT GmbH Method for monitoring and modulating protein folding
DK1448772T3 (da) 2001-11-30 2007-11-19 Serono Lab Fremgangsmåder til forögelse af ekspressionsniveauer af human TNF-receptor
US20030134352A1 (en) 2002-01-04 2003-07-17 Freimuth Paul I. Facilitating protein folding and solubility by use of peptide extensions
EP1468105A2 (en) 2002-01-07 2004-10-20 European Molecular Biology Laboratory Recombinant protein expression
WO2005026196A2 (en) 2003-09-12 2005-03-24 Novexin Limited Methods for folding proteins and reducing protein aggregation
EP3409762A1 (en) 2008-03-17 2018-12-05 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
US8722348B2 (en) * 2008-05-28 2014-05-13 Wayne State University Method and composition for a protein transduction technology and its applications
CA2695590C (en) * 2008-06-27 2018-01-09 Kyoto University Method of efficiently establishing induced pluripotent stem cells
WO2010115052A2 (en) 2009-04-03 2010-10-07 The Mclean Hospital Corporation Induced pluripotent stem cells
WO2010124143A1 (en) * 2009-04-23 2010-10-28 Nevada Cancer Institute Reprogramming of somatic cells with purified proteins
EP2253700A1 (en) 2009-05-13 2010-11-24 Helmholtz-Zentrum für Infektionsforschung GmbH A method for producing test systems from donors suffering from adverse effects of medicaments and /or medical treatments, and uses of said systems
CN101993495B (zh) * 2009-08-12 2013-07-24 上海近岸科技有限公司 一种蛋白质混合物及其制备方法
EP2499237A1 (en) * 2009-11-13 2012-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Reprogrammation of eukaryotic cells with engineered microvesicles
CN101906419A (zh) * 2010-07-29 2010-12-08 中国人民解放军军事医学科学院放射与辐射医学研究所 可用于高效制备诱导性多能干细胞的小分子化合物和方法
ES2957478T3 (es) * 2011-05-02 2024-01-19 Univ Wayne State Una tecnología de células madre pluripotentes inducidas por proteínas y usos de las mismas

Also Published As

Publication number Publication date
EP2705143B1 (en) 2021-02-17
US11685903B2 (en) 2023-06-27
US10640751B2 (en) 2020-05-05
ES2957478T3 (es) 2024-01-19
PT2705143T (pt) 2021-04-07
PL2705143T3 (pl) 2021-07-19
EP3777538A1 (en) 2021-02-17
US20140242695A1 (en) 2014-08-28
EP2705143A2 (en) 2014-03-12
US10221397B2 (en) 2019-03-05
WO2012151234A2 (en) 2012-11-08
ES2866411T3 (es) 2021-10-19
WO2012151234A3 (en) 2014-02-20
US20180127725A1 (en) 2018-05-10
EP2705143A4 (en) 2015-12-16
CN107012118A (zh) 2017-08-04
US20200291362A1 (en) 2020-09-17
US20190161739A1 (en) 2019-05-30
EP3777538B1 (en) 2023-06-28
US9816076B2 (en) 2017-11-14
CN103826459B (zh) 2017-05-10
CN103826459A (zh) 2014-05-28

Similar Documents

Publication Publication Date Title
DK2705143T3 (da) Protein-induceret pluripotent celleteknologi og anvendelse deraf
HK1210494A1 (zh) 用於細胞培養的裝置和方法
DK2855736T3 (da) Elektrolysator og energisystem
DK3346008T3 (da) Rekombinante mikroorganismer og anvendelser deraf
CO7030961A2 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
DK3354665T3 (da) Modificerede alginater til celleindkapsling og celleterapi
DK2850202T3 (da) Fremgangsmåder og grupper
EP2811011A4 (en) CELL CULTURE KIT AND METHOD FOR USING THE CELL CULTURE KIT
DK2837680T3 (da) Mammaliacellekultur
DK3404027T3 (da) Cellekernetransportmodulatorer og anvendelser deraf
DK3045187T3 (da) Injektor og fremgangsmåde til samling
DK3351620T3 (da) Metabolsk optimeret cellekultur
DK3401319T3 (da) Celledyrkningsmedium
SG10201606745XA (en) Therapeutics using adipose cells and cell secretions
CO6870031A2 (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
DK3257943T3 (da) Fremgangsmåder og vektorer til celleimmortalisering
HK1214412A1 (zh) 電化學生物反應器模塊和使用所述模塊的方法
DK3326642T3 (da) Langtidsvirkende koagulationsfaktorer og brugen deraf
DK3567099T3 (da) Nyrecellepopulationer og anvendelser deraf
DK2785683T3 (da) Inkt-cellemodulatorer og fremgangsmåder til anvendelse heraf
DK2600715T3 (da) Flydende ST-246-formuleringer og fremgangsmåder
SG11201503085VA (en) Perfusion culturing methods and uses thereof
DK2795177T3 (da) Flydende metan-lagringssystem og fremgangsmåde
DK2704744T3 (da) Komplementfaktor-b-analoger og anvendelser deraf
DK2753346T3 (da) Ceramidase og celledifferentiering